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Abstract
Background: Lung injury induced by lipopolysaccharide (LPS) remains one of the leading causes of morbidity and
mortality in children. The damage to membrane phospholipids leads to the collapse of the bronchial alveolar
epithelial barrier during acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Phospholipase A2 (PLA2),
a key enzyme in the hydrolysis of membrane phospholipids, plays an important traumatic role in pulmonary
inflammation, and Clara cell secretory protein (CCSP) is an endogenous inhibitor of PLA2. Our previous study
showed that polydatin (PD), a monocrystalline extracted from a traditional Chinese medicinal herb (Polygonum
cuspidatum Sieb, et Zucc), reduced PLA2 activity and sPLA2-IIA mRNA expression and mitigated LPS-induced lung
injury. However, the potential mechanism for these effects has not been well defined. We have continued to
investigate the effect of PD on LPS-induced expression of CCSP mRNA and protein in vivo and in vitro.
Results: Our results suggested that the CCSP mRNA level was consistent with its protein expression. CCSP
expression was decreased in lung after LPS challenge. In contrast, PD markedly increased CCSP expression in a
concentration-dependent manner. In particular, CCSP expression in PD-pretreated rat lung was higher than in rats
receiving only PD treatment.
Conclusion: These results indicated that up-regulation of CCSP expression causing inhibition of PLA2 activation
may be one of the crucial protective mechanisms of PD in LPS-induced lung injury.
Background
Acute lung injury (ALI), or its severe form, acute respira-
tory distress syndrome (ARDS), induced by sepsis is still
a major cause of morbidity and mortality in children [1].
ALI is characterized by an extensive neutrophil influx
into the lung, the expression of proinflammatory media-
tors and damage to the lung epithelium and endothelium.
Current clinical and experimental research on the treat-
ment of lung injury is aimed at inhibiting different stages
of this process with drugs or therapy, along with enhan-
cing the body’s own resistance, to delay or mitigate lung
injury. However, the outcome of sepsis and septic shock
cases has not been improved significantly. Mortality in
ALI is still as high as 18%-27%, and the mortality rate of
(ARDS) is even higher to 29%-50% [2]. Therefore,
improved treatments and prevention strategies are
needed to minimize the mortality associated with ALI.
It is generally acknowledged that damage to membrane
phospholipids leads to the collapse of the bronchial
alveolar epithelial barrier during ALI/ARDS. Phospholi-
pase A2 (PLA2), a key enzyme that hydrolyzes membrane
phospholipids, plays a critical traumatic role in pulmon-
ary inflammation through its influence on membrane sig-
nal transduction, biomembrane stability, activation of
lipid mediators and leukocyte-endothelial cell adhesion
cascade formation. PLA2 hydrolyzes the fatty acid from
the sn-2 position of phospholipids to release arachidonic
acid, prostaglandins, platelet-activating factor and other
inflammatory mediators [3]. In mammals, PLA2 forms a
large family of enzymes that can be schematically divided
into two major classes: high-molecular-weight intracellu-
lar PLA2 (cPLA2) and low-molecular-weight secretory
PLA2(sPLA2), including sPLA2-IIA. The former (cPLA2)
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iating generation of eicosanoids and hence many inflam-
matory processes. The latter (sPLA2)i sf o u n da th i g h
levels in the circulation and locally in the tissues and has
been suggested to play a role in a number of inflamma-
tory diseases by regulating the synthesis of prostaglan-
dins, leukotrienes and platelet activating factor[4].
Especially, recent study showed that sPLA2-IIA catalyzes
the hydrolysis of surfactant phospholipids and suggested
that this process can contribute to the loss of surface ten-
sion-lowering properties of surfactant [5]. Clinically,
sPLA2-IIA offers new possibilities as an early marker for
severe inflammation and predicting systemic complica-
tions in severely ill patients. Thus, PLA2 is regarded as
the core and rate-limiting enzyme of inflammation and
plays an important role in the pathogenesis of LPS-
induced acute lung injury. Specific inhibitors can be used
to elucidate the roles of PLA2 in cellular processes or to
develop new potential therapeutics [6]. Sato R reported
[7] that LY37 4388, an exogenous inhibitor of sPLA2,
may exert a protective effect on LPS-induced acute lung
injury in male C57BL/6J mice.
Clara cell secretory protein (CCSP; also known as
CC16, CC10 and uteroglobin) is a 16-kDa homodimeric
protein that is secreted by non-ciliated bronchiolar
(Clara) cells into the mucus lining the bronchial epithe-
lium of the mammalian lung. It is one of the most abun-
dant proteins in the airway mucus of mammals [8]. As a
biomarker of Clara cells and lung health, CCSP has been
proposed as a useful diagnostic marker of toxicant expo-
sure or airway epithelial damage. Some studies have
reported that administration of exogenous CCSP such as
recombinant human CCSP to the lungs mitigates inflam-
mation [9-11]. Although evidence points to antioxidant
[12], anti-inflammation, immunomodulation, anti-cyto-
kine, pollutant clearance, anti-fibrosis, anti-tumor inva-
sion and anti-protease activity [13], its endogenous
mechanism is not known. Studies on CCSP-deficient
mice have indicated that CCSP acts as an endogenous
inhibitor of PLA2 [14,15] by binding calcium, a cofactor
for secretory PLA2 activation, or phosphatidylcholine, a
substrate of PLA2 [16].
Polydatin (PD), also known as polygonin, is a type of
polyphenolic phytoalexin with strong antioxidative activ-
ity that is isolated from a variety of plant species and also
can be readily synthesized [17,18]. One of the richest
sources of this monocrystalline compound is the roots of
Polygonum cuspidatum Sieb, a weed widely used in tradi-
tional Chinese and Japanese medicine. Its chemical name
is 3, 4’, 5-trihydroxystilbene-3-b-single-D-glucoside [19]
(Figure 1). PD exhibits multiple biological activities and
pharmacological effects, such as protection of the heart
[19,20], brain [21] and liver [22], improving microcircula-
tion [23], inhibiting platelet aggregation [24], combating
shock [25], anti-asthmatic, microbial resistance, and anti-
cancer activities. In 2006, PD was evaluated by the State
Food and Drug Administration of China and became one
of the new drugs approved for further testing in phase II
clinical trials.
Our previous experimental results indicate that polyda-
tin has prophylactic and therapeutic effects (the former is
more distinct than the latter) on acutely injured lungs in
rats with endotoxic shock by inhibiting phospholipase A2
activity and the gene expression of secretory phospholi-
pase A2 type II A (sPLA2-IIA) [26]. Phospholipase A2
activity and sPLA2-IIA expression are increased by endo-
toxin injection, but treatment with polydatin inhibits
these increases. In our preliminary experiments, obvious
morphological evidence was found in pathological lung
sections, and the protective effect of PD was most
obvious in lung from rats pretreated with PD. These
early results suggest that PD may act as a phospholipase
A2 inhibitor to inhibit the activation and activity of PLA2.
However, the potential mechanism is not yet fully under-
stood. Therefore, the purpose of this study was to deter-
mine whether polydatin can up-regulate the expression
of CCSP and inhibit PLA2 to suppress LPS-induced lung
injury.
Methods
In vivo experiments
Animals and grouping
Ninety-eight healthy, male, 7-week-old Sprague-Dawley
rats (clean grade) weighing 200-250 g were purchased
from the Animal Experiment Center of Chongqing Medi-
cal University (Chongqing, China). They were housed in
a regulated environment (24 ± 2°C), with a 12 hours dark
and 12 hours light cycle. All animal treatments were
strictly in accordance with international ethical guide-
lines and the National Institutes of Health Guide for the
Care and Use of Laboratory Animals, and the experi-
ments were carried out with the approval of the
Figure 1 The chemical structure of trans-polydatin (3,4’,5-
trihydroxystilbene-3-b-single-D-glucoside).
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the University.
T h er a t sw e r er a n d o m l yd i v i d e di n t of i v eg r o u p s
(Table 1): the sham operation group (I), endotoxic
shock group (II), PD treatment group (III), PD pretreat-
m e n tg r o u p( I V )a n dP Dc o n t r o lg r o u p( V )( n=1 0
each). The rats in group I were injected with normal sal-
ine and served as the control; the rats in group II were
injected with LPS (10 mg per kg body weight). For
group III and group IV, LPS (10 mg per kg body weight)
was injected, and PD solution was injected 1 hour later
or 0.5 hours before, respectively. The rats in group V
received PD solution only.
PD was administered as a 0.5% solution (0.2 ml per kg
body weight) with a final concentration of 1 mg PD
per kg body weight.
The PD treatment and pretreatment groups were each
further divided into four subgroups (n = 6 each) that
received 1 mg·kg
-1,5m g · k g
-1,1 0m g · k g
-1 or 30 mg·kg
-1
PD, respectively.
Animal model
Rats were fasted overnight but given free access to
water, then anesthetized with 20% urethane (5-6 ml·kg
-1
body weight) intraperitoneally. The left common carotid
artery was separated and catheterized. The canal was
connected to an MS302 biology signal recording and
analyzing system (provided by Guangdong Pharmacolo-
gical Institute in Guangzhou, China) to measure the
mean arterial pressure (MAP). The right cervical vein
was then separated and catheterized. LPS (Sigma, 10 mg
per kg body weight) was injected from the right cervical
vein. After injection, MAP fell from normal to shock
levels (The blood pressure of rat and human being are
almost same). After six hours’ observation, they were
sacrificed with cervical dislocation and their lung tissues
and blood were collected for experiments.
Determining the expressions of CCSP/sPLA2/cPLA2 mRNA
in rat lung with real-time PCR
Total RNA was isolated from lung tissue using Trizol
reagent (Invitrogen). RNA was further purified with the
RNeasy Mini Kit, treated with DNase I (30 U·μg
-1total
RNA) (Qiagen), and then reverse transcribed using the
SuperScript III First-Strand Synthesis System (Invitrogen)
according to the manufacturer’s recommended protocols.
Quantitative gene expression analysis was performed
using the ABI Prism 7000 Sequence Detection System
(Applied Biosystems), with cDNA equivalent to 10 ng of
total RNA and SYBR Green PCR Master Mix (Applied
Biosystems) following the manufacturer’sp r o t o c o l .T h e
following primers (Table 2) were used to amplify CCSP,
sPLA2, cPLA2 and b-actin.
Determining the expression of CCSP mRNA in rat lung with
RT-PCR
Total RNA was extracted from lung tissue using Trizol
reagent, and the first strand of cDNA was synthesized
using reverse transcriptase. The genes of interest were
then amplified by PCR. Primers corresponding to the
genes of interest were the same as those mentioned
previously.
Determining the content of CCSP protein in rat lung with
western blotting
Human CCSP (Biovendor) was used as the half-quantita-
tion standard. Protein was isolated from tissues that were
homogenized in a buffer (containing protein lysates). The
quantity of protein from the lung homogenate depended
on the size of lung issue we used. The concentration of
total protein was 10 μg·μl
-1. The total protein of each
sample for measuring was 10 μg. Samples were then
combined with loading buffer containing 10% glycerol,
10% 2-mercapthanol, 2% SDS, and bromophenol blue in
0.07 M Tris-HCL (pH 6.8, boiled for 5 minutes), resolved
by SDS-PAGE and then transferred to a membrane for
western blotting. The membrane was incubated with a
blocking solution (5% skim milk) at 24°C for 2 hours. A
primary antibody was then added to the solution and
incubated at 4°C for 12 hours. A peroxidase-conjugated
secondary antibody solution was used to incubate the
membrane at 24°C for 1 hour. The membranes were then
incubated with a chemiluminescent substrate (Thermo
34077) and exposed to film (Millipore IPVH00 10).
Determining the concentration of CCSP protein in rat serum
with ELISA
Four milliliters of blood was collected from the aorta,
mixed with 1% heparin to anticoagulate for 10-20 minutes
and then centrifuged for 20 minutes (2000-3000 × g).
Table 1 Animal grouping and drug injection
Group 0 h 0.5 h 1 h 2 h 6 h
I begin NS NS NS sacrifice
II begin NS LPS NS sacrifice
III begin NS LPS PD sacrifice
IV begin PD LPS NS sacrifice
V begin PD NS NS sacrifice
Table 2 PCR primer pairs used amplify CCSP, sPLA2,
cPLA2 and b-actin cDNA fragments of rat lung
Target Oligonucleotide sequence Tm (°C) bp
b-actin F: 5’-AGAGGGAAATCGTGCGTGAC-3’ 60 195
R: 5’-CCATACCCAGGAAGGAAGGCT-3’
CCSP F: 5’-CGGACATCTGCCCAGGATTTCT-3’ 60 209
R: 5’-ACACAGAGGACTTGTTAGGAT-3’
sPLA2 F: 5’-CCCCAAGGATGCCACAGATT-3’ 60 201
R: 5’-TTCCGGGCAAAACATTCAGC-3’
cPLA2 F: 5’-GAAGTTTGCTCATGCCCAGACCT-3’ 60 234
R: 5’-TTCATAGAGCGCCTTCATCACACC-3’
F, forward primer; R, reverse primer; Tm, melting temperature.
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concentration of CCSP protein was measured by ELISA
according to the manufacturer’s instructions (Rat CCSP
ELISA kit, Westang, F15255; Rabbit polyclonal to Utero-
globin, ab4 0873, Abcam).
Measuring CCSP positive cells with immunohistochemistry
Biopsy samples were fixed by immersion in Bouin’s fluid,
paraffin-embedded and cut into 6-μm-thick sections.
CCSP-immunoreactive cells were detected with the utero-
globin antibody (Abcam, ab40873) and the immunoperoxi-
dase technique. The number of CCSP-positive and
-negative bronchiolar cells was determined for each
bronchiolar profile examined in the lung biopsies by count-
ing all surface epithelial cells on the bronchial biopsy speci-
mens. For each sample, the proportion of CCSP-positive
cells was expressed as a percentage of the whole bronchio-
lar epithelium cell population examined.
In vitro experiments
Cells culture
All cell lines used in this study were purchased from the
American Type Culture Collection (Manassas, VA).
BEAS-2B cells are human bronchial epithelia cells trans-
formed by the SV40 T-antigen. BEAS-2B cells were cul-
tured in LHC-8 medium (Gibco, America) and incubated
at 37°C in an atmosphere of 5% CO2 and 95% air. The
medium was replaced every second day, and cells were
passaged when > 85% confluent by washing with Ca
2+-
and Mg
2+-free PBS and dislodging with 0.05% trypsin.
MTT assay was used to determine the suitable concentra-
tions of PD and LPS.
Cells grouping
Cells were divided into five groups: the normal control
group, containing cultured BEAS-2B cells under normal
conditions for 28 hours; the LPS group, containing cul-
tured BEAS-2B cells in LHC-8 medium treated with LPS
(100 ng·ml
-1) for 28 hours to mimic a LPS-induced inflam-
matory response model; the PD treatment group, contain-
ing cultured BEAS-2B cells challenged with LPS
(100 ng·ml
-1) in LHC-8 medium for 24 h, followed by PD
treatment (0.5 m mol·L
-1 in LHC-8 medium) for 4 h; the
PD pretreatment group, containing cultured BEAS-2B
cells that were pretreated with PD (0.5 m mol·L
-1)i n
LHC-8 medium for 4 hours, followed by an LPS challenge
(100 ng·ml
-1) in LHC-8 medium under normal conditions
for 24 hours; and the PD control group, containing cul-
tured BEAS-2B cells treated with PD (0.5 m mol·L
-1)i n
LHC-8 medium for 28 hours.
Determining the expression of CCSP mRNA in BEAS-2B cells
Total RNA was isolated from cells using Trizol reagent
(Invitrogen) according to the manufacturer’s instructions.
RNA was further purified with an RNeasy Mini Kit and
treated with DNase I (30 U·μg
-1 total RNA) then reverse-
transcribed using the Super Script III First-Strand
Synthesis System according to the protocols supplied by
the manufacturer. Quantitative gene expression analysis
was performed using the ABI Prism 7000 Sequence
Detection System, with cDNA equivalent to 10 ng of
total RNA and SYBR Green PCR Master Mix following
the manufacturer’s protocol. The following primers
(Table 3) were used to amplify CCSP and b-actin.
Determining the expression of CCSP protein in BEAS-2B
Cells were washed with phosphate-buffered saline and
lysed in lysis buffer. Lysates were subjected to 4% to
15% SDS-PAGE and western blotting with anti-c-kit
(1:100) antibody. Immunopositive bands were visualized
by enhanced chemiluminescence (ECL, Amersham).
Blots were stripped and reprobed with GAPDH antibody
(1:2000) as a control to ensure equal loading.
Statistical analysis
A l ld a t aw e r ee x p r e s s e da st h em e a n±S E M .D a t aw e r e
analyzed with SSPS for Windows 13.0 using one-way
analysis of variance (ANOVA) and the Bonferroni cor-
rection for multiple comparisons, when appropriate. In
all cases, P values less than 0.05 was considered statisti-
cally significant.
Results
Polydatin up-regulates CCSP mRNA expression in rat lung
A significant decrease CCSP mRNA expression was
observed only in the endotoxic shock group five hours after
LPS injection (Figure 2A/2B-group II). PD can increase
CCSP mRNA expression not only in normal rat lung
(Figure 2A/2B, group V vs. group I) but also in rat lung
following endotoxic shock(Figure 2A/2B-group III/IV).
Moreover, CCSP mRNA level in the PD pretreatment
group was significantly higher (P < 0.05) than in the PD
treatment group (Figure 2A/2B-group III/IV, group IV vs.
group III). PD increased CCSP mRNA expression in a
dose-dependent manner (Figure 3A-1, A-2, B-1 and 3B-2).
Polydatin down-regulates sPLA2 and cPLA2 mRNA
expression in rat lung
Because CCSP was the potential inhibitor of PLA2,w e
investigated the effects of PD on PLA2 along with CCSP.
PD could down-regulate the levels of sPLA2 and cPLA2
mRNA expressions in normal rat lung (Figure 4A/4B,
Table 3 PCR primer pairs used amplify CCSP and b-actin
cDNA fragments of BEAS-2B cells
Target Oligonucleotide sequence Tm (°C) bp
CCSP F: 5’- GAAACTCGCTGTCACCCTCACC-3’ 60 211
R: 5’-TTAATGATGCTTTCTCTGG-3’
b-actin F: 5’-CCTGTACGCCAACACAGTGC-3’; 60 234
R: 5’-ATACTCCTGCTTGCTGATCC-3’
F, forward primer; R, reverse primer; Tm, melting temperature.
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the levels of sPLA2 and cPLA2 mRNA expressions of rat
lung induced by LPS (Figure 4A/4B-group III/IV), in a
dose-dependent manner (Figure 5A, B and Figure 6A, B).
The expression of sPLA2 and cPLA2 in PD pretreatment
g r o u pw a sl o w e rt h a ni nP Dt r e a t m e n tg r o u p( F i g u r e4 A
and 4B, group IV vs. group III, P < 0.05).
Polydatin up-regulates CCSP protein expression in rat
lung
To investigate whether CCSP protein expression chan-
ged with its mRNA expression synchronously, we
detected CCSP protein in lung by western blot. The
results indicated that LPS not only inhibited the protein
expression of CCSP but also that PD treatment and PD
pretreatment increased the level of CCSP markedly (Fig-
ure 7A and 7B). In particular, CCSP protein in the pre-
treatment and PD control groups was significantly
higher than in the sham operation group (Figure 7A/7B,
group IV and V vs. group I). CCSP protein expression
in the PD pretreatment group was higher than in PD
treatment group (Figure 7A/7B, group IV vs. group III).
Thus, PD increased CCSP protein expression in a dose-
dependent manner (Figure 8A-1, A-2, B-1 and 8B-2).
Figure 2 Effects of polydatin on the expression of CCSP mRNA in rat lung. A. Relative expression of CCSP, quantified by real-time PCR. B.
Electrophoresis showing the RT-PCR results. I: sham operation group, injected with normal saline; II: endotoxic shock group, injected with LPS
(10 mg·kg
-1 body weight); III: PD treatment group, injected with LPS (10 mg·kg
-1 body weight), then a 0.5% PD solution (0.2 ml·kg
-1 body weight)
1 hour later; IV: PD pretreatment group, injected with a 0.5% PD solution (0.2 ml·kg
-1 body weight), then LPS (10 mg·kg
-1 body weight) 0.5 hours
later; V: PD control group.
cP < 0.01 vs. group I;
eP < 0.05 and
fP < 0.01 vs. group II;
iP < 0.05 vs. group III.
Figure 3 The dose-effect relationship between polydatin and CCSP mRNA expression in rat lung. A. CCSP mRNA expression in PD treatment
groups with different doses by real-time PCR (A-1) and RT-PCR(A-2). B. CCSP mRNA expression in PD pretreatment groups with different doses by
real-time PCR (B-1) and RT-PCR(B-2).
bP < 0.05 vs. 1 mg·kg
-1 PD group,
eP < 0.05 vs. 5 mg·kg
-1PD group, and
jP < 0.01 vs. 10 mg·kg
-1 PD group.
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Page 5 of 13Figure 4 Effects of polydatin on the expression of sPLA2/cPLA2 mRNA in rat lung. A. Relative expression of sPLA2, quantified by real-time
PCR. B. Relative expression of cPLA2, quantified by real-time PCR. I: sham operation group, injected with normal saline; II: endotoxic shock group,
injected with LPS (10 mg·kg
-1 body weight); III: PD treatment group, injected with LPS (10 mg·kg
-1 body weight), then a 0.5% PD solution (0.2
ml·kg
-1 body weight) 1 hour later; IV: PD pretreatment group, injected with a 0.5% PD solution (0.2 ml·kg
-1 body weight), then LPS (10 mg·kg
-1
body weight) 0.5 hours later; V: PD control group.
bP < 0.05 and
cP < 0.01 vs. group I;
fP < 0.01 vs. group II;
iP < 0.05 and
jP < 0.01 vs. group III.
Figure 5 The dose-effect relationship between polydatin and sPLA2 mRNA expression in rat lung. A. sPLA2 mRNA expression in PD
treatment groups with different doses by real-time PCR and RT-PCR. B. sPLA2 mRNA expression in PD pretreatment groups with different doses
by real-time PCR and RT-PCR.
cP < 0.01 vs. 1 mg·kg
-1 PD group,
eP < 0.05 and
fP < 0.01 vs. 5 mg·kg
-1PD group, and
iP < 0.05 vs. 10 mg·kg
-1 PD
group.
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CCSP can transfer from lung tissue into the blood
serum. Serum CCSP level is closely related to its synth-
esis and secretion by Clara cells in the respiratory tract,
and serum CCSP level may act as a marker of the
bronchoalveolar blood-gas barrier integrity and perme-
ability [27,28]. As shown in Figure 9, serum CCSP level
in the endotoxin shock group was significantly higher
than in the sham operation group(Figure 9, group II vs.
group I). However, CCSP levels in the PD treatment
and PD pretreatment groups were lower than in the
endotoxic shock group (Figure 9, group III/IV vs. group
II). Serum CCSP level decreased with increasing PD
dose (Figure 10A/10B). Therefore, PD decreased CCSP
transference from lung to serum in a dose-dependent
manner.
Polydatin increases the percentage of CCSP-positive cells
In rat lung slices, CCSP-positive cells are non-ciliated
epithelial cells, namely, Clara cells. The relative CCSP-
positive airway epithelial cell proportions were as follows.
Compared with the sham operation group, CCSP-positive
Figure 6 The dose-effect relationship between polydatin and cPLA2 mRNA expression in rat lung.A .c P L A 2 mRNA expression in PD
treatment groups with different doses by real-time PCR. B. cPLA2 mRNA expression in PD pretreatment groups with different doses by real-time
PCR.
cP < 0.01 vs. 1 mg·kg
-1 PD group,
eP < 0.05 and
fP < 0.01 vs. 5 mg·kg
-1PD group, and
iP < 0.05 vs. 10 mg·kg
-1 PD group.
Figure 7 Effects of polydatin on the expression of CCSP protein in rat lung. CCSP protein expression was examined by western blot. I:
sham operation group; II: endotoxic shock group; III: PD treatment group; IV: PD pretreatment group; V: PD control group. A. The
electrophoretogram of CCSP protein expression. B. Relative ratio of CCSP protein expression.
bP < 0.05 and
cP < 0.01 vs. group I;
eP < 0.05 and
fP
< 0.01 vs. group II;
iP < 0.05 vs. group III.
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and increased in the PD control group (Table 4). Com-
pared with the LPS group, CCSP-positive cells were
increased in the PD treatment and pretreatment groups
(Table 4). Thus, PD increased CCSP-positive cells in lung
tissue in a dose-dependent manner (Table 5).
Polydatin up-regulates CCSP expression in BEAS-2B
T h eM T Ta s s a ys u g g e s t e dt h a tt h em o s ts u i t a b l ec o n -
centration of PD to use in BEAS-2B cells was 0.5 mmol/
L and the most suitable concentration of LPS was 10
ng·ml
-1. In vitro, LPS led to reduced CCSP expression in
BEAS-2B cells, while PD promoted CCSP expression,
not only in normal BEAS-2B cells but also in LPS-
induced BEAS-2B cells (Figure 11 and 12). In addition,
CCSP expression in the PD pretreatment group was
greater than in the PD treatment group (Figure 11 and
12).
Discussion
There are many experimental models of acute lung
injury, but none of them completely reproduces all the
prominent features of human ALI/ARDS, such as alveo-
lar neutrophilia (indicating inflammation), hyaline mem-
brane deposition (indicating disruption of the alveolar-
capillary barrier) and microthrombi (indicating endothe-
lial injury). Hence, there is no single “best” model of
lung injury; instead, the best model will be one that
reproduces the features to be tested in the investigator’s
hypothesis.
We used one of the well-established rat models of
acute lung injury, intravenous administration of LPS
because it can lead to activation of various inflammatory
mediators such as phospholipase A2.T h e s em e d i a t o r s
may cause epithelial lesions and increase the alveoloca-
pillary barrier permeability. Therefore, this model met
all the requirements for our purpose.
First, we observed a reduction of CCSP mRNA in par-
allel with decreased CCSP protein expression in rat lung
tissue after LPS stimulation for five hours. Prior to this,
we knew that different inflammatory stimuli result in
Figure 8 Dose-effect relationship between polydatin and CCSP protein expression in rat lung. A.CCSP protein expression in PD treatment
groups with different doses. B.CCSP protein expression in PD pretreatment groups with different doses.
bP < 0.05 vs. 1 mg·kg
-1 PD group,
eP<
0.05 and
fP < 0.01 vs. 5 mg·kg
-1PD group, and
iP < 0.05 vs. 10 mg·kg
-1 PD group.
Figure 9 Effects of polydatin on serum CCSP level in different
groups of rats. I: Sham operation group; II: endotoxic shock group;
III: PD treatment group; IV: PD pretreatment group; V: PD control
group.
bP < 0.05 vs. group I;
fP < 0.01 vs. group II.
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O3 and injection of phenyl isothiocyanate can induce
acute and chronic inflammation in humans and increase
CCSP expression in lung [27]. By contrast, CCSP pro-
duction is decreased during acute and chronic lung
injury caused by viral and bacterial infections, smoking
[29] or chronic obstructive pulmonary disease. All of
these factors make the role of CCSP in the inflammatory
process more complex. Moreover, CCSP expression may
Figure 10 Dose-effect relationship between polydatin and serum CCSP level in rat. A.Serum CCSP level in PD treatment groups with
different doses. B. Serum CCSP level in PD pretreatment groups with different doses.
bP < 0.05 and
cP < 0.01 vs. 1 mg·kg
-1 PD group,
fP < 0.01
vs. 5 mg·kg
-1PD group, and
iP < 0.05 vs. 10 mg·kg
-1 PD group.
Table 4 Percentage of CCSP-positive cells of lung tissue
in each group (¯ x ± s, n = 10)
Group The percentage of CCSP positive cells
I 20.3 ± 2.4
II 13.2 ± 1.3
b
III 37 ± 4
be
IV 46 ± 6
cf
V5 3 ± 6
cf
I: sham operation group; II: endotoxic shock group; III: PD treatment group; IV:
PD pretreatment group; V: PD control group.
bP < 0.05 and
cP < 0.01 vs.
group I;
eP < 0.05 and
fP < 0.01 vs. group II.
Table 5 Percentage of CCSP-positive cells of lung tissue
in each group (¯ x ±s ,n=6 )
Group Dosage (mg·kg
-
1)
Percentage of CCSP-positive
cells
PD
pretreatment
1 40.2 ± 2.3
55 4 ± 3
b
10 63.5 ± 2.6
f
15 79 ± 3
i
PD treatment 1 37.4 ± 2.4
54 6 ± 3
c
10 56.8 ± 2.4
f
15 70 ± 4
j
bP < 0.05 and
cP < 0.01 vs. 1 mg·kg
-1 PD group,
fP < 0.01 vs. 5 mg·kg
-1PD
group,
iP < 0.05 and
jP < 0.01 vs. 10 mg·kg
-1 PD group.
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rather than the inflammation itself [30]. It is most likely
that up-regulation of CCSP expression is a result of the
body’s self-protection mechanism in the early stages of
the inflammatory response, but suppression of CCSP
expression follows during the later inflammatory
response. CCSP expression is down-regulated after acute
lung inflammation induced by intratracheal or intrave-
nous LPS administration [28,31]. Our results are in
agreement with these previous experimental observa-
tions. The finding that LPS reduces CCSP expression
should provide an excellent foundation for future
research.
Second, polydatin increased the CCSP-positive cell per-
centage and up-regulated CCSP mRNA and protein
expression in lung tissue during acute lung injury induced
by LPS. CCSP expression was increased along with PD
increasing. There was a dose-effect relationship between
PD and CCSP expression within our observational dose
range. Additionally, CCSP protein expression was consis-
tent with its mRNA level. Some possible mechanism by
which PD promotes CCSP expression can be explained as
follows: 1) PD can increase the number of CCSP-positive
cells (i.e., Clara cells); 2) PD can promote the secretion of
CCSP in individual Clara cells to increase total CCSP
expression; and 3) most importantly, PD can enhance the
stability of CCSP. The reduction of CCSP degradation is
an important factor in increasing CCSP level. PD can help
to keep the bronchoalveolar blood-gas barrier integrity
and decrease the bronchoalveolar blood-gas barrier per-
meability induced by LPS so that CCSP will not be decom-
posed in serum. Berg et al [32] have reported that
glucocorticoids regulate the CCSP promoter via C/EBP
beta and -delta in lung cells. Ramsay et al. [33] have
Figure 11 Effects of polydatin on CCSP mRNA expression in LPS-induced BEAS-2B cells. A. Relative expression of CCSP quantified by real-
time PCR. B. RT-PCR analysis shown by electrophoresis.
bP < 0.05 vs. normal control group;
eP < 0.05 and
fP < 0.01 vs. LPS group;
iP < 0.05 vs.
LPS+PD group.
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CCSP in rat and rabbit lung tissue. The reported mechan-
isms are as follows: 1) regulation of the Th1/Th2 cytokine
network to increase CCSP mRNA expression; 2) hormone
receptor and IFN-gbinding sites exist in the 5’-flanking
region of the CCSP gene, which can directly promote the
transcription of the CCSP gene and increase the synthesis
and secretion of CCSP; and 3) increased stability of CCSP
mRNA at the post-transcriptional level. Therefore, our
future research will be focused on the effect of polydatin
on the transcription of CCSP.
Third, CCSP expression in lung in the PD pretreatment
group was greater than in the PD treatment group. This
result suggests that a competitive inhibition of CCSP
exists between PD and LPS. Therefore, we propose that
PD and LPS have a common binding site in Clara cells
that can influence the secretion of CCSP. However, the
specific mechanism remains unclear, and the intrinsic
link between PD and CCSP requires further investigation.
Fourth, based on animal experiments, the BEAS-2B
cell line was chosen as the model to study the effect of
PD on CCSP in vitro. BEAS-2B cells are clara cells that
have been transformed by the SV40 T-antigen. BEAS-2B
is the most commonly used model for CCSP research
[34,35]. The human CCSP gene exists as a single copy
in BEAS-2B cells. Tumor necrosis factor-a (TNF-a)c a n
induce a change in chromosome structure that enhances
the stability of an RNA-binding protein involved in tran-
scriptional regulation, which increases CCSP gene
expression in BEAS-2B cells [36]. Kim et al. [37] have
reported that IL-13 and other indirectly acting proteins
can promote the expression and activation of epidermal
growth factor receptor (EGFR) so as to increase CCSP
expression in airway epithelium. We found that CCSP
can be expressed in and secreted by BEAS-2B cells in
culture medium. LPS can decrease CCSP expression in
BEAS-2B cells, while PD can promote the expression of
CCSP in normal and LPS-stimulated cells, and the
change in mRNA is consistent with CCSP protein
expression. PD may enhance the proliferation of Clara
cells and it may enhance the proliferation of CCSP-posi-
tive/pro-surfactant protein C pro-SPC-positive cells [38].
As far as the limitation of this research work was con-
cerned, we just observed that polydatin suppressed
Figure 12 Effects of polydatin on CCSP protein levels in LPS-induced BEAS-2B cells. A. The electrophoretogram of CCSP protein
expression. B. Relative ratio of CCSP protein expression.
cP < 0.01 vs. normal control group;
eP < 0.05 and
fP < 0.01 vs. LPS group;
iP < 0.05 vs.
LPS+PD group.
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Page 11 of 13PLA2 of lung induced by LPS through up-regulating
Clara cell secretory protein. The intrinsic relationship
between PD and CCSP need further investigation.
Conclusion
We have demonstrated that PD can modulate CCSP
expression to inhibit PLA2. This inhibition is probably a
crucial protection mechanism of PD in LPS-induced
acute lung injury. These findings provide compelling
evidence for the potential efficacy of PD in clinical use,
although the molecular mechanisms of its action need
further exploration.
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